Olaparib Patent Expiration
Olaparib is Used for treating various types of cancers, including breast, ovarian, pancreatic, and metastatic prostate cancer, in patients with specific gene mutations undergoing specific chemotherapy regimens. It was first introduced by Astrazeneca Pharmaceuticals Lp
Olaparib Patents
Given below is the list of patents protecting Olaparib, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Lynparza | US11970530 | Methods of treating homologous recombination deficient cancer | Oct 25, 2041 | Astrazeneca |
Lynparza | US8859562 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer | Aug 04, 2031 | Astrazeneca |
Lynparza | US8475842 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Dec 31, 2029 | Astrazeneca |
Lynparza | US11633396 | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one | Oct 07, 2029 | Astrazeneca |
Lynparza | US11975001 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Oct 07, 2029 | Astrazeneca |
Lynparza | US12048695 | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Oct 07, 2029 | Astrazeneca |
Lynparza | US8247416 | Phthalazinone derivative | Sep 24, 2028 | Astrazeneca |
Lynparza | US7449464 | Phthalazinone derivatives | Sep 08, 2027 | Astrazeneca |
Lynparza | US8071579 | DNA damage repair inhibitors for the treatment of cancer | Aug 12, 2027 | Astrazeneca |
Lynparza | US8143241 | DNA damage repair inhibitors for treatment of cancer | Aug 12, 2027 | Astrazeneca |
Lynparza | US7449464 | Phthalazinone derivatives |
Oct 11, 2024
(Expired) | Astrazeneca |
Lynparza | US7981889 | Phthalazinone derivatives |
Oct 11, 2024
(Expired) | Astrazeneca |
Lynparza | US8912187 | Phthalazinone derivatives |
Mar 12, 2024
(Expired) | Astrazeneca |
Lynparza | US9169235 | Phthalazinone derivatives |
Mar 12, 2024
(Expired) | Astrazeneca |
Lynparza | US9566276 | Phthalazinone derivatives |
Mar 12, 2024
(Expired) | Astrazeneca |
Lynparza | US7151102 | Phthalazinone derivatives |
Apr 29, 2022
(Expired) | Astrazeneca |
Olaparib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List